CASTLE BIOSCIENCES INC 8K

Castle Biosciences furnished an investor presentation reporting strong Q2 2026 test volume and financial performance, raised 2026 revenue guidance, detailed clinical and commercial progress of its test portfolio, and noted expanded access for its AdvanceAD-Tx test and a solid cash position.

Castle Biosciences, Inc. furnished an investor presentation as an exhibit to its Form 8-K outlining second quarter 2026 operating and financial results and strategic updates, highlighting a 32% year-over-year increase in test volume for its core revenue drivers (DecisionDx-Melanoma and TissueCypher), total Q2 2026 revenue of $103.5 million with adjusted gross margin of 76.3% and adjusted EBITDA of $12.4 million, a strong liquidity position with $266.8 million of cash, cash equivalents and marketable securities as of June 30, 2026, raised full-year 2026 revenue guidance to $365–375 million from $345–355 million, expansion of market access for its AdvanceAD-Tx test via New York State Department of Health assay approval, and continued clinical and commercial progress across its dermatology, gastroenterology and ophthalmology test portfolio, supported by extensive clinical evidence and non-GAAP performance metrics.

Filing Facts

CIK

1447362

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-051045

Alert Tier

6